The goal of the ALTER CAR project is to develop novel, alternative, chimeric antigen receptor (CAR)-based therapeutic solutions for leukemia and lymphoma patients with poor prognosis.
The collaboration within the Consortium provides a unique opportunity to implement CAR T cell technology in Poland and develop alternative CAR T cells with new specificities, which may constitute a significant advancement in CAR therapy. The long-term outcome of the project will be the establishment of a sustainable Polish-Norwegian network for the development, production and preparation of CAR-based and other adoptive therapies for clinical studies in various forms of cancer.
